基于循证医学的临床决策支持解决方案 可缓解医生压力

2013-12-02 MedSci MedSci原创

医生面临的压力越来越大,他们需要在有限的时间内诊治大量患者,此外,人们还希望医生能够跟上瞬息万变的新医学发现并将其融于临床实践,这也给医生们带来了莫大的压力。时间太少,需要处理信息的太多,加之资源匮乏,诊断错误的发生机率便大大增加。临床决策支持(Clinical Decision Support,CDS)解决方案能够明显改善以上情况。特别值得一提的是,与为医生提供太多提示的CDS技术不同,循证医学

医生面临的压力越来越大,他们需要在有限的时间内诊治大量患者,此外,人们还希望医生能够跟上瞬息万变的新医学发现并将其融于临床实践,这也给医生们带来了莫大的压力。时间太少,需要处理信息的太多,加之资源匮乏,诊断错误的发生机率便大大增加。

临床决策支持(Clinical Decision Support,CDS)解决方案能够明显改善以上情况。特别值得一提的是,与为医生提供太多提示的CDS技术不同,循证医学(Evidence-based Medicine,EBM)的CDS解决方案,能针对诊断与治疗的临床问题提供可行、详细且证据充分的解答以支持快速准确地做出正确的诊断和合适的治疗方案。

时间有限、海量信息的双重压力

全球著名咨询机构益普索(Ipsos)最近进行的一项执业医生调查,突显了时间过于有限和信息太多这一双重压力因素。参与调查的医生指出的前10大挑战,包括诊治患者的時间(88%)、跟上最新的研究步伐(83%)以及管理不断增长的患者数量(73%)。

问题并不仅仅停留在有限的时间上面,海量的新信息也开始产生影响。一名医生每天需要阅读19篇期刊论文才能勉强跟上每年发表的2百万篇科技论文的速度。这是新的医学证据平均需要经过17年才能被用于临床实践的原因之一。另一个为医生带来压力的因素是缺乏相应的指导、指南来帮助医生
确定新发现何时才具有改变临床实践的临床意义。

由于必须独自进行判断,加上时间有限,许多医生只得继续使用已过时的方法來诊治患者。

近年,医生们开始试图使用互联网来跟上变化的步伐。调查发现,虽然专业期刊仍然是首要资源(84%),但医生同时在很大程度上也依赖搜索引擎查找信息(80%),如百度、谷歌(Google)和雅虎(Yahoo)。

使用"谷歌医生(Dr.Google)"非常普遍,但这实际上也可能会使问题更加复杂。多项研究早已显示,每三项临床诊断中,就会产生两个问题,而如果这些问题能及时得到解答,那么每天可改变五到八个临床诊断管理决策。遗憾的是,在此类问题中,通常只能解决40%。部分原因是因为一般的网络搜索会产生上百种相关或不相关的结果,而其来源通常并不能让人一目了然或值得信赖。当患者在诊断室等待时,医生没有时间去评估搜索结果的可靠度并决定其是否适用。

CDS的有效性:资源必须可信、可用

解决以上错综复杂问题的方法,是更加广泛地采用能够在诊断与治疗时快速回答临床问题的CDS资源。医生们已经肯定,通过使用CDS能够解决大约90%的问题。大量研究显示,CDS与诊断、管理以及获得医学知识等方面的重大临床改变之间存在一定联系。

CDS,特别是循证医学为基础的UpToDate,能提升医疗机构的质量与效率,包括缩短住院期和降低死亡率。同时,能针对诊断与治疗的临床问题提供可行、详细且证据充分的解答,证明了其对改善治疗的质量、安全性和效率等的影响力。

因此,CDS已经成为管理海量临床信息的关键工具,帮助医生建立对其治疗决定的信心。CDS资源不仅能辅助医生进行差别化诊断,还能满足对认知支持系统更广泛的需求,协助进行诊断和管理决策。

为了保证有效,CDS资源必须提供可信、便于访问的信息,提供医生最需要的解答。CDS资源必须针对临床问题给出快速简洁的回答,提供与问题高度相关的信息。UpToDate相信:最理想的是,提供由各个临床领域专家根据最新医学文献,并详细评估后而编撰的原创内容;同样关键的是,所有新的医学证据都必须经过相同严格的评估,提供可能改变普遍临床治疗方法的新发现,并且提供分级建议让医生可以有信心地根据建议进行诊治。

此外,访问这类信息的方式也非常重要。调查证实,许多医生都知道移动设备正迅速地成为访问临床信息的首选工具。百分之八十的医生表示在其日常诊治中使用智能手机,百分之六十的医生使用平板电脑,超过一半的医生同时使用智能手机和平板电脑。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1723189, encodeId=da951e2318922, content=<a href='/topic/show?id=ab292269213' target=_blank style='color:#2F92EE;'>#临床决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22692, encryptionId=ab292269213, topicName=临床决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=810a33379458, createdName=wwzzly, createdTime=Sat Jan 04 18:00:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987973, encodeId=91ee198e97342, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Jan 30 21:00:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379437, encodeId=a45c13e94370e, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Wed Dec 04 13:00:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449650, encodeId=269a14496501d, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Wed Dec 04 13:00:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541754, encodeId=2c3a1541e54a8, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e76e13331157, createdName=ms2999106592497887, createdTime=Wed Dec 04 13:00:00 CST 2013, time=2013-12-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1723189, encodeId=da951e2318922, content=<a href='/topic/show?id=ab292269213' target=_blank style='color:#2F92EE;'>#临床决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22692, encryptionId=ab292269213, topicName=临床决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=810a33379458, createdName=wwzzly, createdTime=Sat Jan 04 18:00:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987973, encodeId=91ee198e97342, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Jan 30 21:00:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379437, encodeId=a45c13e94370e, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Wed Dec 04 13:00:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449650, encodeId=269a14496501d, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Wed Dec 04 13:00:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541754, encodeId=2c3a1541e54a8, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e76e13331157, createdName=ms2999106592497887, createdTime=Wed Dec 04 13:00:00 CST 2013, time=2013-12-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1723189, encodeId=da951e2318922, content=<a href='/topic/show?id=ab292269213' target=_blank style='color:#2F92EE;'>#临床决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22692, encryptionId=ab292269213, topicName=临床决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=810a33379458, createdName=wwzzly, createdTime=Sat Jan 04 18:00:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987973, encodeId=91ee198e97342, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Jan 30 21:00:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379437, encodeId=a45c13e94370e, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Wed Dec 04 13:00:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449650, encodeId=269a14496501d, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Wed Dec 04 13:00:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541754, encodeId=2c3a1541e54a8, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e76e13331157, createdName=ms2999106592497887, createdTime=Wed Dec 04 13:00:00 CST 2013, time=2013-12-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1723189, encodeId=da951e2318922, content=<a href='/topic/show?id=ab292269213' target=_blank style='color:#2F92EE;'>#临床决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22692, encryptionId=ab292269213, topicName=临床决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=810a33379458, createdName=wwzzly, createdTime=Sat Jan 04 18:00:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987973, encodeId=91ee198e97342, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Jan 30 21:00:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379437, encodeId=a45c13e94370e, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Wed Dec 04 13:00:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449650, encodeId=269a14496501d, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Wed Dec 04 13:00:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541754, encodeId=2c3a1541e54a8, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e76e13331157, createdName=ms2999106592497887, createdTime=Wed Dec 04 13:00:00 CST 2013, time=2013-12-04, status=1, ipAttribution=)]
    2013-12-04 xjy04
  5. [GetPortalCommentsPageByObjectIdResponse(id=1723189, encodeId=da951e2318922, content=<a href='/topic/show?id=ab292269213' target=_blank style='color:#2F92EE;'>#临床决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22692, encryptionId=ab292269213, topicName=临床决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=810a33379458, createdName=wwzzly, createdTime=Sat Jan 04 18:00:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987973, encodeId=91ee198e97342, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Jan 30 21:00:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379437, encodeId=a45c13e94370e, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Wed Dec 04 13:00:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449650, encodeId=269a14496501d, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Wed Dec 04 13:00:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541754, encodeId=2c3a1541e54a8, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e76e13331157, createdName=ms2999106592497887, createdTime=Wed Dec 04 13:00:00 CST 2013, time=2013-12-04, status=1, ipAttribution=)]